AU2012212162A1 - Methods and compositions for increasing sialic acid production and treating sialic related disease conditions - Google Patents

Methods and compositions for increasing sialic acid production and treating sialic related disease conditions Download PDF

Info

Publication number
AU2012212162A1
AU2012212162A1 AU2012212162A AU2012212162A AU2012212162A1 AU 2012212162 A1 AU2012212162 A1 AU 2012212162A1 AU 2012212162 A AU2012212162 A AU 2012212162A AU 2012212162 A AU2012212162 A AU 2012212162A AU 2012212162 A1 AU2012212162 A1 AU 2012212162A1
Authority
AU
Australia
Prior art keywords
gne
nucleic acid
cell
subject
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012212162A
Other languages
English (en)
Inventor
Daniel Darvish
Yadira Valles-Ayoub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HIBM Research Group Inc
Original Assignee
HIBM Research Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HIBM Research Group Inc filed Critical HIBM Research Group Inc
Publication of AU2012212162A1 publication Critical patent/AU2012212162A1/en
Priority to AU2017203027A priority Critical patent/AU2017203027B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
    • A61M5/425—Protruding skin to facilitate piercing, e.g. vacuum cylinders, vein immobilising means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012212162A 2011-02-01 2012-02-01 Methods and compositions for increasing sialic acid production and treating sialic related disease conditions Abandoned AU2012212162A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017203027A AU2017203027B2 (en) 2011-02-01 2017-05-05 Methods And Compositions For Increasing Sialic Acid Production And Treating Sialic Related Disease Conditions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438585P 2011-02-01 2011-02-01
US61/438,585 2011-02-01
PCT/US2012/023536 WO2012106465A2 (en) 2011-02-01 2012-02-01 Methods and compositions for increasing sialic acid production and treating sialic related disease conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017203027A Division AU2017203027B2 (en) 2011-02-01 2017-05-05 Methods And Compositions For Increasing Sialic Acid Production And Treating Sialic Related Disease Conditions

Publications (1)

Publication Number Publication Date
AU2012212162A1 true AU2012212162A1 (en) 2013-08-29

Family

ID=46603295

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012212162A Abandoned AU2012212162A1 (en) 2011-02-01 2012-02-01 Methods and compositions for increasing sialic acid production and treating sialic related disease conditions
AU2017203027A Ceased AU2017203027B2 (en) 2011-02-01 2017-05-05 Methods And Compositions For Increasing Sialic Acid Production And Treating Sialic Related Disease Conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017203027A Ceased AU2017203027B2 (en) 2011-02-01 2017-05-05 Methods And Compositions For Increasing Sialic Acid Production And Treating Sialic Related Disease Conditions

Country Status (9)

Country Link
US (2) US20130030040A1 (enExample)
EP (2) EP2670442A4 (enExample)
JP (2) JP2014506787A (enExample)
KR (2) KR102257741B1 (enExample)
AU (2) AU2012212162A1 (enExample)
CA (1) CA2863578C (enExample)
IL (1) IL227773B (enExample)
MX (1) MX365095B (enExample)
WO (1) WO2012106465A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057856A1 (en) * 2012-08-22 2014-02-27 The Regents Of The Universtiy Of California Compositions and Methods For Enhancing Sialic Acid Levels In Tissue
US20150322439A1 (en) * 2012-11-19 2015-11-12 Nature Technology Corporation Replicative minicircle vectors with improved expression
US20140256639A1 (en) * 2013-02-14 2014-09-11 The Regents Of The University Of California Peptoid neutralizing agents
CN103088090B (zh) * 2013-03-01 2014-06-04 南京工业大学 一种n-乙酰葡萄糖胺异构酶在生产n-乙酰甘露糖胺中的应用
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
KR102765034B1 (ko) 2017-05-24 2025-02-11 유니버시타트 아우토노마 데 바르셀로나 섬유아세포 성장 인자 21 (ｆｇｆ21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트
CN108285886A (zh) * 2018-01-30 2018-07-17 江南大学 重组枯草芽孢杆菌全细胞转化生产n-乙酰神经氨酸的方法
US11865165B2 (en) * 2018-09-18 2024-01-09 Daniel DARVISH GNE as a therapeutic agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173465A9 (en) 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
WO2001059075A1 (en) * 2000-02-08 2001-08-16 Genentech, Inc. Improved sialylation of glycoproteins
US20060218669A1 (en) * 2003-02-11 2006-09-28 Lokesh Joshi Sialylation of glycoproteins in plants
US20070073264A1 (en) * 2003-09-26 2007-03-29 The Trustees Of The University Of Pennsylvania Methods, compositions and apparatus for delivering heterologous molecules to cells
WO2008001023A1 (en) 2006-06-27 2008-01-03 Gigabeam Corporation Cellular communication system
JP5415283B2 (ja) * 2007-02-07 2014-02-12 グラダリス インク． シアル酸産生を調節し、遺伝性封入体ミオパチーを治療する方法及び組成物
WO2008124934A1 (en) 2007-04-17 2008-10-23 National Research Council Of Canada Constructs for enhancement of gene expression in muscle
US9018174B2 (en) * 2008-05-28 2015-04-28 Hibm Research Group, Inc. Mouse model and treatment of hereditary inclusion body myopathy
EP2324110A4 (en) 2008-09-09 2013-01-09 Univ California ELIMINATION OF A CONTAMINATING NON-HUMAN SIALIC ACID BY METABOLISM COMPETITION
US9045759B2 (en) * 2009-01-21 2015-06-02 James Arthur Williams DNA plasmids with improved copy number
WO2011096750A2 (en) * 2010-02-08 2011-08-11 Korea Advanced Institute Of Science And Technology Method for preparing recombinant glycoproteins with high sialic acid content

Also Published As

Publication number Publication date
EP3202425A1 (en) 2017-08-09
IL227773B (en) 2021-03-25
US20140275230A1 (en) 2014-09-18
AU2017203027B2 (en) 2019-08-15
JP2014506787A (ja) 2014-03-20
JP2017158577A (ja) 2017-09-14
MX365095B (es) 2019-05-22
IL227773A0 (en) 2013-09-30
KR102257741B1 (ko) 2021-05-28
EP2670442A2 (en) 2013-12-11
WO2012106465A2 (en) 2012-08-09
US10098969B2 (en) 2018-10-16
KR20140034150A (ko) 2014-03-19
MX2013008948A (es) 2014-02-18
US20130030040A1 (en) 2013-01-31
KR20190108178A (ko) 2019-09-23
AU2017203027A1 (en) 2017-07-20
CA2863578C (en) 2021-10-26
CA2863578A1 (en) 2012-08-09
EP2670442A4 (en) 2015-07-29
WO2012106465A3 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
AU2017203027B2 (en) Methods And Compositions For Increasing Sialic Acid Production And Treating Sialic Related Disease Conditions
KR101535791B1 (ko) 개량형 이듀로네이트-2-설파타제 및 이의 용도
Wang et al. A bioengineered probiotic for the oral delivery of a peptide Kv1. 3 channel blocker to treat rheumatoid arthritis
US11510999B2 (en) Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
EP3747461A1 (en) Asparaginase-based cancer therapy
US20240285734A1 (en) Gne as a therapeutic agent
KR102228271B1 (ko) 항암활성을 갖는 면역조절 단백질-siRNA 복합체
US20220088223A1 (en) Methods and compositions for increasing sialic acid production and treating sialic related disease conditions
US20190374652A1 (en) Methods and compositions for increasing sialic acid production and treating sialic related disease conditions
WO2019078586A1 (en) TREATMENT OF NEUROPATHY WITH DNA CONSTRUCTION EXPRESSING HGF ISOFORMS WITH REDUCED INTERFERENCE FROM GABAPENTINOIDS
Girald et al. Toxicity and delivery methods for the linamarase/linamarin/glucose oxidase system, when used against human glioma tumors implanted in the brain of nude rats
CN107208108B (zh) 缺血性疾病治疗药
CN119700704B (zh) 一种靶向递送小干扰核酸的组装型蛋白纳米载体CABRi及其制备方法和应用
US20240254495A1 (en) Therapeutic Engineered Microbial Cell Systems and Methods for Treating Conditions in Which Oxalate is Detrimental
JP2002154976A (ja) 慢性疾患の予防、改善及び／又は治療剤並びに健康食品
Pergolizzi et al. 374. Development of a Genetic Vaccine Conferring Protective Immunity Against [alpha]-Cobratoxin Following a Single Administration of an Adenovirus Vector Encoding a Modified, Non-Toxic Cobratoxin Variant
JP2025510150A (ja) パーキンソン病の処置のための方法および組成物
KR20240015030A (ko) E5의 분비를 위한 재조합 발현 벡터 및 이로 형질전환된약독화 살모넬라 균주
Kozlowski et al. 376. A Metabolically Responsive Insulin Transgene Delivered by AAV2/8 Pseudotyped, Self-Complementary AAV (SC-AAV2/8) Controls Glycemia in STZ-Diabetic Mice
CN109055389A (zh) 携带人胰高血糖素样肽１(7-36)基因的重组质粒
WINEARLS Renal Unit, Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London W12 OHS.
HK1159123B (en) Novel polypeptide for resisting tumors caused by eb (epstein-barr) viruses, and application and preparation method thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted